Skip to main content

Mats Ohlin

The molecular evolution group


Welcome to this information page. My name is Mats Ohlin and I am one of the professors at the Department of Immunotechnology, Lund University. Our department is involved in research on the application of immunology in technology, therapy and diagnosis. My research is mainly focused on the characterization and use of human antibodies and human antibody technology for such purposes.

My research

My own research focus was originally on human monoclonal antibody technology involving regular cell cloning techniques. Over the past decades, however, aspects involving molecular biology approaches to human antibody research including phage display technology has been a major interest of mine as well as of the antibody community in general.

My research groups

My research groups has extended the utility of such tools for specific purposes and employed them to further our understanding of antibodies in health and disease. We have also extended the utility of these molecular evolution tools to the development of carbohydrate binding molecules of a different origin. 


Below you will find brief summaries of some of the various project that I have been or are involved in. In addition I head the Lund branch of Science for Life Laboratory's Human Antibody Therapeutics National Facility, a part of SciLifeLab's Drug Discovery and Development Platform, a platform that offers integrated drug discovery efforts to the Swedish academic research community. If you have any comments or questions, please do not hesitate to contact me on any of these matters.

Mats Ohlin.

Professor Mats Ohlin

Head of the Department
+46 46 222 43 22
skype: matsohlin

Department of Immunotechnology
Lund University
Medicon Village
Building 406
223 81 LUND

Short summary

  • Professor: Lund University, 2003
  • Lecturer: Lund University, 1997
  • Assoc. Prof: Lund University, 1995
  • PhD: Lund University, 1993
  • Co-founder: Immunovia AB, 2007
  • Award: Excellent Teaching Practitioner, 2008

Page Manager: | 2021-04-09